

RESEARCH ARTICLE

Open Access



The alpha-synuclein oligomers activate nuclear factor of activated T-cell (NFAT) modulating synaptic homeostasis and apoptosis

Ricardo Sant'Anna^{1,2†}, Bruno K. Robbs^{3†}, Júlia Araújo de Freitas², Patrícia Pires dos Santos¹, Annekatrin König¹, Tiago Fleming Outeiro^{1,4,5,6*} and Debora Foguel^{2*} 

Abstract

Background Soluble oligomeric forms of alpha-synuclein (aSyn-O) are believed to be one of the main toxic species in Parkinson's disease (PD) leading to degeneration. aSyn-O can induce Ca^{2+} influx, over activating downstream pathways leading to PD phenotype. Calcineurin (CN), a phosphatase regulated by Ca^{2+} levels, activates NFAT transcription factors that are involved in the regulation of neuronal plasticity, growth, and survival.

Methods Here, using a combination of cell toxicity and gene regulation assays performed in the presence of classical inhibitors of the NFAT/CN pathway, we investigate NFAT's role in neuronal degeneration induced by aSyn-O.

Results aSyn-O are toxic to neurons leading to cell death, loss of neuron ramification and reduction of synaptic proteins which are reversed by CN inhibition with ciclosporin-A or VIVIT, a NFAT specific inhibitor. aSyn-O induce NFAT nuclear translocation and transactivation. We found that aSyn-O modulates the gene involved in the maintenance of synapses, synapsin 1 (*Syn 1*). *Syn 1* mRNA and protein and synaptic *puncta* are drastically reduced in cells treated with aSyn-O which are reversed by NFAT inhibition.

Conclusions For the first time a direct role of NFAT in aSyn-O-induced toxicity and *Syn 1* gene regulation was demonstrated, enlarging our understanding of the pathways underpinning synucleinopathies.

Keywords Alpha-synuclein, Synucleinopathies, Parkinson's disease, NFAT, Synapsin 1, Synapses

[†]Ricardo Sant'Anna and Bruno K. Robbs contributed equally to this work.

*Correspondence:

Tiago Fleming Outeiro

touteir@gwdg.de

Debora Foguel

foguel@bioqmed.ufrj.br

¹ Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Waldweg 33, 37073 Göttingen, Germany

² Centro de Ciências da Saúde, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Bloco E sala 42, Rio de Janeiro 21941-590, Brazil

³ Departamento de Ciência Básica, Instituto de Saúde de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, RJ 28625-650, Brazil

⁴ Max Planck Institute for Multidisciplinary Sciences, 37075 Göttingen, Germany

⁵ Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK

⁶ Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany



Introduction

Parkinson's disease (PD) is characterized by a preferential loss of dopaminergic (DA) neurons in the *substantia nigra* and accumulation of intracellular inclusions known as Lewy bodies (LB) and Lewy neurites (LN). These inclusions are primarily made up of the protein alpha-synuclein (aSyn) (Spillantini et al. 1997), an abundant presynaptic and nuclear protein (Pinho et al. 2019; Koss et al. 2022), possibly playing a role in vesicular trafficking and synaptic vesicle biology (Hurtley 2010). In Lewy body diseases, aSyn is thought to aggregate into fibrils that are the main components of LB and LN (Spillantini et al. 1997; Braak et al. 1999). The accumulation of these deposits is accompanied by inflammation, progressive neuronal dysfunction and, eventually, death of affected neuronal populations, leading to the various clinical features of the disease (Braak et al. 2003, 2005; Caviness et al. 2011). Several missense mutations in the *SNCA* gene, which encodes for aSyn, are linked to rare forms of familial PD (Polymeropoulos et al. 1997; Krüger et al. 1998; Zarranz et al. 2004; Singleton et al. 2003; Chartier-Harlin et al. 2004; Fujioka et al. 2014; Conway et al. 1998), suggesting aSyn may gain a toxic function that possibly contributes to disease. Although aSyn and its mutants can form amyloid fibers in vitro, and accumulate in LBs in the brain, aSyn fibrils have been hypothesized to be protective, by sequestering the more toxic intermediate aggregates such as oligomers (Olanow et al. 2004). This is consistent with the observation that, in certain juvenile forms of PD, extensive neurodegeneration is observed in the absence of LB formation (Olanow et al. 2004; Baba et al. 1998; Takahashi et al. 1994). In addition, it has also been shown that LB-bearing neurons may not exhibit cytotoxic phenotypes (Gertz et al. 1994; Tompkins et al. 1997; Osterberg et al. 2015). Furthermore, in vitro and in vivo experiments have illustrated that aSyn oligomers (aSyn-O) are toxic to neural cells, while fibrils are not (Kayed et al. 2003; Outeiro et al. 2008; Winner et al. 2011). Interestingly, some aSyn mutants, such as A30P, have a higher propensity to form oligomers than fibers (Lee et al. 2004; Lázaro et al. 2014), which is advantageous for testing phenotypes associated with the accumulation of oligomeric aSyn species.

An implication of the theories of spreading of aSyn pathology (Braak et al. 1999; Kordower et al. 2008; Brundin et al. 2008) is the occurrence of aSyn extracellular species. In fact, such species were shown to be of pathological relevance in various experimental paradigms (Lee 2008; Brown 2010; Diógenes et al. 2012). aSyn-O can be released from cultured cells and primary neurons (Emmanouilidou et al. 2010; Foulds et al. 2011; Danzer et al. 2011), and are detectable in the soluble protein fraction of brains of patients with LB dementia (El-Agnaf

et al. 2006; Paleologou et al. 2009), as well as in the cerebral spinal fluid of PD patients (El-Agnaf et al. 2006). Importantly, the occurrence of extracellular aSyn-O in other synucleinopathies suggests they may be relevant not only in PD but also in other related disorders (Lee 2008).

One of the possible effects of extracellular oligomeric forms of aSyn is the induction of Ca^{2+} influx into neurons and glial cells, and the consequent activation of downstream pathways, leading to pathological alterations and, ultimately, to cell death (Martin et al. 2012; Caraveo et al. 2014; Ferreira et al. 2017).

Calcineurin (CN) is largely responsible for transducing signals generated by changes in Ca^{2+} levels (Li et al. 2011). CN is a calmodulin-dependent serine/threonine phosphatase. Pharmacological inhibition of calcineurin catalytic subunit (calcineurin A; CnA), with a clinically used inhibitor such as FK506 can reduce aSyn toxicity in different models (Martin et al. 2012; Caraveo et al. 2014). The family of transcription factors (TF) named nuclear factor of activated T-cell (NFAT), which includes NFATc1, NFATc2, NFATc3 and NFATc4, is the main family of TF downstream of CN (Crabtree 1999). In resting cells, NFAT proteins are hyperphosphorylated and reside mainly in the cytoplasm. Upon activation, NFAT undergoes rapid CnA-dependent dephosphorylation and translocate to the nucleus, where they regulate gene transcription (Mognol et al. 2016). The immunosuppressive drugs cyclosporin A (CsA) and FK506, which are well-known inhibitors of CnA, inhibit NFAT activity by blocking its dephosphorylation (Park et al. 1995; Loh et al. 1996). More recently a new and specific NFAT inhibitor called VIVIT has been described inhibiting only the interaction of CN/NFAT, but not inhibiting the activity of the enzyme (Aramburu et al. 1999; Noguchi et al. 2004). Although the family of NFAT transcription factors was initially characterized in the immune system, recent studies have highlighted the importance of this family of proteins in neurons, where they are involved in the regulation of synaptic plasticity, axonal growth, and neuronal survival (Graef et al. 2003). NFAT proteins directly regulate the expression of apoptosis-related genes such as *Fas-L*, *Nur77*, *c-Flip* and with the promotion of inflammatory process such as *TNF- α* , *COX-2* and *IL1- β* in different cell types (Mognol et al. 2016; Robbs et al. 2013; Lucena et al. 2016). Both, apoptosis and inflammation are processes widely involved in the development of PD. However, the involvement of NFAT in aSyn-mediated degeneration of mesencephalic DA (mDA) neurons is unclear.

Here, we investigated the role of NFAT signaling in the cellular pathology and loss of synaptic proteins associated with extracellular aSyn. We demonstrate that aSyn-O induce cell death in primary DA neurons and

neuroblastoma cells in a CN/NFAT dependent fashion, since its inhibition completely abolishes the toxic effect of the oligomers. Accordingly, after the analysis of a panel of 91 genes related to various cellular processes involved in PD/synucleinopathies by real-time qPCR, and further validation at protein level, we found that aSyn-O modulate the gene involved in the maintenance of synapses, synapsin 1 (*Syn1*). *Syn1* mRNA and protein and synaptic *puncta* are drastically reduced in cells treated with aSyn-O. Furthermore, we show for the first time the presence of two conserved putative NFAT binding site in the promoter regions of *Syn1* gene and that NFAT specific inhibition rescues synapsin 1 transcripts and protein to normal levels. To our knowledge, this is the first demonstration of a direct role of NFAT in aSyn-O-induced toxicity and *Syn1* gene regulation, with implication to synucleinopathies.

Methods

A30P-aSyn purification

Purification of A30P-aSyn mutant was performed according to Conway et al. (1998). The cDNA encoding the aSyn was cloned into the expression plasmid (pET21) and transformed by heat shock into the *Escherichia coli* strain (BL21DE3). Bacteria were cultured at 37 °C under shaking at 180 rpm in the presence of 100 µg/mL ampicillin until reaching the Optical Density (OD) of 0.6 at 600 nm. Induction of the expression of the protein was performed using 500 mM isopropyl 1-thiol-β-galactopyranoside (IPTG) (Bioagency). Cells were then kept under the same conditions for 4 h and collected by centrifugation at 6000 rpm for 15 min at 4 °C. The supernatant was discarded, and the pellet resuspended in lysis buffer (50 mM Tris, 50 mM KCl). The solution was sonicated for 30 min/30 s intervals at 4 °C. Cell debris was removed by centrifugation at 13,000 rpm for 20 min at 4 °C. The sample was then boiled for 15 min and centrifuged at 13,000 rpm for 20 min. After centrifugation, the volume of the supernatant was measured and transferred to a beaker, added 361 g/L of (NH₄)₂SO₄, stirred for 30 min and again centrifuged. In order to remove salt, the precipitate was resuspended in 25 mM Tris buffer pH 7.5 and dialyzed 4 times against H₂O milliQ in a final volume of 4 L at 4 °C on a 3500 Da pore membrane (Spectrum™ Spectra/Por™ Fischersci). Subsequently, the sample was applied to an ion exchange column (Source 30Q GE Healthcare) initially equilibrated with 25 mM Tris buffer pH 7.5, and a 0 to 1 M NaCl gradient was performed. The presence of protein was verified by the absorbance of the samples at 280 nm. The samples corresponding to aSyn were collected, dialyzed against H₂O milliQ, aliquoted into 1 mL tubes and lyophilized for 18 h. The samples were then resuspended in phosphate buffer (PBS) and

loaded onto an 18% SDS-PAGE gel. In addition, prior to use, the samples were subjected to a new purification step by exclusion chromatography on a Superdex 200 column (GE Healthcare®). The system was equilibrated with PBS buffer at a flow rate of 0.5 mL/min. The elution was monitored by absorbance at 280 nm and the peak corresponding to the monomer was collected and used in all assays.

The samples were concentrated by ultrafiltration in an AMICON system (Millipore) with a 10,000 Da exclusion membrane. The concentration of aSyn samples was estimated by measuring the absorbance at 280 nm using the extinction coefficient of 5960 M⁻¹ cm⁻¹.

A30P-aSyn oligomerization and aggregation

After purification and confirmation of the purity of the sample, aSyn was incubated at the concentration of 140 µM in PBS pH 7.5 under sterile conditions, under agitation at 800 rpm and 37 °C in a Thermo-Shaker for TS-100 microtubes (Biosan) for up to 10 days. A 5 µL aliquot of the aSyn protein not incubated or incubated for different periods under aggregating conditions was transferred to a nitrocellulose membrane (Bio-rad®; 0.45 µm). The sample was then blocked with Odyssey™ blocking buffer for 60 min at 22 °C. After this period, the membrane was incubated with primary antibody against aSyn (Monoclonal anti-human mouse α-synuclein Syn211 Invitrogen™), against A11 oligomers (Polyclonal Rabbit Anti-amyloid oligomer A11 AB9234 Millipore™) and against amyloid fibers OC (Polyclonal Rabbit Anti-amyloid fibers OC AB2286 Millipore™) all at 1:1000 dilution for 18 h at 4 °C. After the incubation period, the membrane was washed 5 times under agitation for 5 min each wash with 0.1% PBS-Tween20. After washing, the membrane was incubated with antibody against IgG at a dilution of 1:10,000, in Odyssey™ blocking buffer + 0.1% PBS, which can be anti-rabbit or mouse depending on the host of the primary antibody. Incubation took place for 2 h at 22 °C under gentle agitation and then the membrane was washed 5 times with 0.1% PBS-Tween20 under agitation for 5 min each wash and kept in PBS buffer protected from light. The membrane was then digitized and scanned in the appropriate channel (700 nm for Cy5.5 antibody and 800 nm for IRDye™ antibody using the Odyssey Infrared Imaging System instrument).

Atomic force microscopy (AFM)

Topographic AFM images were obtained at room temperature using TappingMode® AFM with Dimension ICON (Novascan). Images were acquired using Si3N4 oxide AFM (K ~ 3 N/m) cantilever (Model: OTESPA). The scan rate was 0.5 Hz, and the scan resolution was 512 per line. The images were subjected to baseline adjustment

with 2nd order polynomial when necessary to reduce the effects of curvature and skew of the images. To obtain the images, 5 μ L of samples aggregated for different periods were applied on a previously cleaved mica. The samples were in contact with the mica for 5 min and washed with 100 μ L of MilliQ water. The samples adsorbed onto the mica were then incubated at room temperature for 24 h to dry.

Detection of aSyn fibrillization using Thioflavin-T

A Thioflavin-T (Th-T) assay was performed to characterize the species of aSyn present at different times of aggregation. Th-T is a dye widely used to detect amyloid fibrils, since its fluorescence increases upon binding specifically to those structures. Fluorescence spectra of Th-T were obtained using the ISS-PC1 spectrofluorometer (ISS, Champaign, IL) with excitation at 450 nm and the emitted light was detected in the range between 470 and 530 nm. An aliquot of aSyn sample was mixed with Th-T in PBS buffer before measurement. The ratio between the concentration of aSyn and Th-T (Sigma) was 1:10 in all assays.

Primary culture of dopaminergic and hippocampal neurons

C57BL6 animals were used from the 15th embryonic day (E15). Mice were bred and maintained under specific pathogen free conditions in the animal facility of the University Medical Center Göttingen (Göttingen, Germany). Animal procedures were performed in accordance with the European Community (Directive 2010/63/EU), institutional and national guidelines (license number 19.3213). Females were euthanized by cervical dislocation and pups removed and transferred to a petri dish containing PBS buffer at 22 °C. With the aid of a magnifying glass, the brains were removed from the cranial vault and the region corresponding to the ventral tegumentary area (VTA) was dissected to obtain dopaminergic neurons. The tissue was then dissociated, first mechanically using forceps and then with 0.03% trypsin/PBS for 5 min at 37 °C. Cells were seeded in 24-well plates with polylysine coated coverslips at a density of 60,000 cells per well. Cultures were maintained in Neurobasal medium (Gibco®) supplemented with 1% B27 (Invivo-cell®). The experiments were performed after 14 days of neuron maturation in vitro.

For primary hippocampal neuronal cultures from E18 animals were used. The meninges were removed, and the hippocampi were dissected and transferred to ice-cold 1× Hanks balanced salt solution (CaCl₂ and MgCl₂ free; HBSS) (Gibco Invitrogen, CA, USA) supplemented with 0.5% sodium bicarbonate solution (Sigma-Aldrich, MO, USA) and enzymatic digested. Then, the cell suspension

was centrifuged again at 300×g for 5 min, and cells were resuspended in pre-warmed neurobasal medium (Gibco Invitrogen, CA, USA) supplemented with 1% penicillin–streptomycin (Pan Biotech, Aidenbach, Germany), 0.5% GlutaMax and 2% B27 (Gibco Invitrogen, CA, USA). were maintained at 37 °C with 5% CO₂, and one-third of the medium was changed every 3–4 days.

Neuroblastoma 2-a (N2a) cell culture

N2a cells (ATCC® CCL-131TM) originated from murine neuroblastomas were maintained in DMEM culture medium “Dulbecco’s modified Eagles medium” (Gibco®) supplemented with 10% Fetal Bovine Serum (FBS) (Invivo-cell®), 4 mM of L-glutamine (Sigma®), 100 units/mL penicillin and 100 μ g/mL streptomycin at 37 °C in 5% CO₂. The cells were kept under these conditions until they reached 80% confluence, where they were either transferred to a new bottle containing new medium or seeded in plates for the assays.

Differentiation of N2a cells in dopaminergic neurons

Differentiation of N2a cells into dopaminergic neurons was performed as described by Tremblay et al. (2010) and Latge et al. (2015). Cells were seeded in 6-well plates for Western blot and qPCR analysis at a density of 2.0×10^5 and in 24-well plates for toxicity and NFAT transactivation assays or on coverslips at a density of 1.5×10^3 for immunofluorescence analysis. They were maintained for 24 h in DMEM medium supplemented with 10% FBS (Invivo-cell®), 4 mM L-glutamine (Sigma®), 100 units/mL of penicillin and 100 μ g/mL of streptomycin at 37 °C in 5% CO₂. After the rest period, the maintenance medium was removed and replaced by the differentiation medium, which consists of DMEM supplemented with 0.5% FBS (Invivo-cell®), 4 mM L-glutamine (Sigma®), 100 units/mL of penicillin, 100 μ g/mL streptomycin and 1 mM N6,2'-O-dibutyryl adenosine 3',5'-cyclic sodium monophosphate salt (dbcAMP) (Sigma®). Cells were maintained with the differentiation medium at 37 °C in 5% CO₂ for 3 days.

Immunofluorescence analysis

N2a cells or primary dopaminergic neurons were fixed with 4% paraformaldehyde for 20 min at room temperature, permeabilized with Triton X-100 (1% in PBS) for 4 min at room temperature and incubated with Odyssey™ blocking buffer for 1 h at the same temperature condition. N2a cells were then incubated with polyclonal anti-TH (tyrosine hydroxylase; 1:100, Millipore) and anti-MAP2 (1:100; Millipore) antibodies to probe differentiation and with anti-NFAT (NFATc3, Santa Cruz Biotechnology) for the NFAT translocation experiments in Odyssey™ blocking buffer+0.1% Triton X-100.

Primary cells from dopaminergic neurons were incubated with anti-MAP2 (1:100; Millipore) and anti-synapsin 1 (1:200; Millipore) polyclonal antibody under the same conditions. Then, they were washed with PBS and incubated with secondary antibodies conjugated to Alexa Fluor 488 (1:1000 anti-rabbit; Molecular Probes) and Alexa Fluor 546 (1:500 anti-mouse; Molecular Probes) for 18 h at 4 °C. Cells were then washed with PBS, stained with DAPI (300 nM), washed three more times with PBS and mounted. N2a cells were photographed using an Evos[®] microscope (AMG, FL Cell Imaging System), with a 20× objective, or a Fluoview FV10i (Olympus Co.) laser scanning confocal microscope, with a 100× objective. Dopaminergic neurons were imaged using the Zeiss Axioplan Microscope (LSM800, Zeiss, USA), with a 100× objective. All images of both cell types were processed using ImageJ software.

Cell viability assays

To determine the toxicity in N2a cell lines and in primary cultures of dopaminergic neurons, a commercial kit for membrane integrity determination (based on LDH release), cytoTox-ONE[™] Homogeneous Membrane Integrity Assay (Promega[®]) was used. The tests were performed according to the manufacturer's instructions. After 14 days of maturation of the primary neuron cultures in vitro, the cells were treated with vehicle (PBS) or the stated concentrations of monomeric, oligomeric and fibrillar aSyn. When indicated, cells were pretreated for 20 min with cyclosporine (CsA) or VIVIT (Calbiochem). After 24 h of incubation at 37 °C with 5% CO₂, the culture supernatant was collected, and the protocol suggested by the manufacturer was performed. In cultures of the N2a cell line, cells were seeded in 24-well plates with coverslips at a density of 2.0×10^3 cells per well. After 24 h of incubation at 37 °C and 5% CO₂, the cells were subjected to the cAMP differentiation protocol. After the differentiation period, the cells were treated as stated before for primary neurons in culture.

Violet crystal cell proliferation assay

N2a cells were differentiated as described above in 96-well plates, 2.0×10^3 cells per well, in triplicate. Then, they were treated with 10 μM of aSyn oligomers with or without previous treatment with 10 μM of VIVIT. After 24 h, the level of toxicity was assessed by crystal violet staining. Crystal violet staining consists of fixing the cells with absolute ethanol for 10 min, staining the fixed cells with 0.005% crystal violet in 20% ethanol for 10 min, washing with distilled water, solubilizing the crystal violet with methanol for 5 min and read the plate absorbance in a spectrophotometer at 595 nm.

Analysis of cell death by propidium iodide labeling

For cell death analysis, differentiated N2a cells were grown in 6-well plates at a density of 2.0×10^5 per well. Then, they were treated with 10 μM of aSyn oligomers with or without previous treatment with 10 μM of VIVIT. After 24 h of treatment, cells were trypsinized and washed once with PBS buffer. Cells were labeled with propidium iodide (PI) (5 μg/mL). Cell death analysis was determined by collecting 10,000 events by flow cytometry (FACScalibur).

Analysis of gene expression by real-time PCR

Differentiated N2a cells were treated with 10 μM of aSyn oligomers with or without pretreatment with 10 μM of VIVIT for 16 h. CA-NFATc2-ER N2a cells (see below) were treated with vehicle or 150 nM Tamoxifen. RNA from these cultures was extracted and purified using the RNeasy Kit (QIAGEN). Quantification of purified RNA was measured using a Nanodrop-UV-visible spectrophotometer (Thermo Scientific) and RNA integrity was determined by analyzing 28S and 18S ribosomal mRNA bands on an agarose gel. The cDNA was synthesized using the KIT Quantitec Transcription KIT (QIAGEN) as recommended by the manufacturer. Real-time polymerase chain reaction (RT-PCR) was performed using SYBR Green PCR Master mix (Applied Technologies) on QuantStudio3 Real-Time PCR System (Applied Biosystems) according to the manufacturer's instructions. The quality of the primers was tested through the analysis of the dissociation curve (melting curve). In the first Real-Time round, we used a panel of 91 genes known to be involved in the process of programmed cell death, dynamics and formation of dendritic spines and neuronal synapses with possible implications for PD. Primers were synthesized by the company Real Time Primers. The list of these genes and their sequences are presented in Additional file 1: Table S1.

NFAT nuclear translocation

N2a cells were differentiated and treated with oligomers of aSyn. After treatment, the cells were fixed with 4% paraformaldehyde and followed by the immunocytochemistry described protocol, using DAPI for nuclear labeling and anti-NFAT (NFATc3, Santa Cruz Biotechnology). Cover slides were mounted and observed on a Fluoview FV10i (Olympus Co.) laser scanning confocal microscope to reveal cellular disposition of NFAT. The quantification of the translocation was performed with ImageJ. Nuclear region was determined by the DAPI staining. The intensity of red (NFAT) signal on nucleus or on the cytoplasm was used to calculate the ratio of translocation.

NFAT transactivation

To study the NFAT transactivation induced by aSyn oligomers, we used co-transfection experiments with the reporter plasmid pGL4.30 (Promega) that contains upstream to the Firefly luciferase sequence 3× a binding sequence for NFAT, and the plasmid pRL-SV40 (Renilla luciferase) that is under constitutive expression promoters and allows the normalization of transcription data. In these assays, the measurement of the luminescence generated by the luciferases allows comparing the degree of NFAT activation under the conditions tested. N2a cells were seeded at 70% confluence on 24-well plates and differentiation was induced. After 72 h, cells were transfected with Eugene HD (Promega) using DNA:reagent ratio 1:3. Twenty-four hours later, the cells were treated with ionomycin, aSyn oligomers or pre-incubated also with CsA and VIVIT. After more 18 h, the luminescence detection assay was performed following all the manufacturer's recommendations (Dual-Luciferase Reporter Assay Kit System E1910 (Promega).

CA-NFATc2-ER N2a cells construction

To confirm that cell death in differentiated N2a cultures treated with aSyn oligomers is caused by activation of NFAT and to analyze gene transcription under NFAT regulation in our models, we used a N2a strain stably transduced with CA-NFATc2-ER. Briefly, retroviral plasmid pLIREs-EGFP-CA-NFATc2-ER was constructed as described in Robbs et al. (2013). The BD EcoPack2 ectropic packaging cell line (BD-Biosciences) was transiently transfected with a retroviral vector via calcium phosphate precipitation for 24 h. Cell-free virus-containing supernatant was collected 48 h after transfection, mixed 1:1 with fresh medium, supplemented with 8 µg/mL polybrene (FLUKA Chemie, Buchs, Switzerland), and immediately used for spin-infection (2×45 min at 420×g, room temperature) of 2.5×10^4 N2a cells. Infected cells were incubated at 37 °C for an additional 24 h. Afterwards, transduced cells were selected with G418 (Invitrogen) at 1000 µg/mL for 14 days where all remaining cells were GFP positive. In this chimera, the estrogen receptor truncated in the N-terminal region, and responsive only to the drug tamoxifen, is linked to the C-terminal portion of NFATc2. When tamoxifen (4-hydroxytamoxifen from Invitrogen) binds to the estrogen receptor, NFATc2 is activated (Robbs et al. 2013). We treated differentiated CA-NFATc2-ER N2a cultures with different concentrations of tamoxifen.

Statistical analysis

All statistical analysis were performed with GraphPad Prism 5.0 software (GraphPad, San Diego, CA) from at least three independent experiments. Significance was

calculated using One-Way ANOVA test with Dunnett's posttest with multiple comparison against untreated or control sample where $p < 0.05$ were significant. Data are presented as means ± SD.

Results

A30P-aSyn oligomer-induced cytotoxicity and synapses loss is mediated by the calcineurin pathway

Previously, we have demonstrated that ectopic applied recombinant aSyn aggregates are toxic to primary cultures of mDA neurons (Follmer et al. 2007; Braga et al. 2011). Here, we used the same approach to ask if differently aged aggregates of A30P-aSyn added to neurons in culture, in the absence or in the presence of the Calcineurin A (CnA) inhibitor, cyclosporin A (CsA), would remain toxic. First, we probed which species of A30P-aSyn, namely monomers, oligomers, or fibrils, would be cytotoxic to primary dopaminergic neurons in culture. Characterization of all these species is shown in Additional file 1: Fig. S1. Consistently with previous studies, only oligomers (A30P-aSyn-O) were toxic to these cells, causing ~45% of cell death. However, when cells were pre-incubated with CsA, there was a significant reduction in oligomer-induced cytotoxicity (Fig. 1A). Furthermore, we quantified the number of neurons per field in those samples and, again, we found in the A30P-aSyn-O sample a reduction of 60% in the number of neurons. CsA reverted the cytotoxicity induced by A30P-aSyn-O, reducing cell death, and restoring neuronal arborization (Fig. 1B, C).

Next, the effects of the different species composed of A30P-aSyn on synapse formation, stabilization and morphology were investigated. It has been previously demonstrated that oligomeric aSyn reduce the levels of synapsin-1 as well as its localization in presynaptic vesicles, which correlates with cognitive impairment in patients (Larson et al. 2017). Treatment of dopaminergic neurons with A30P-aSyn-O, but not with monomers, led to a drastic reduction in the number of synapses containing synapsin-1 loaded vesicles. Again, this effect was completely abolished by CsA treatment (Fig. 2). Together, these data support a major role for the calcineurin pathway in A30P-aSyn-O induced neural degeneration.

The toxic effects of aSyn oligomers are mediated by the calcineurin-NFAT pathway leading to NFAT translocation into the nucleus activating reporter genes

To further investigate the role of CnA and the possible involvement of the NFAT transcription factor pathway in these cellular models of PD, we differentiated N2a cells into dopaminergic phenotype by treating the cells with butyryl AMPc in reduced serum medium for 72 h, as previously described (Tremblay et al. 2010; Wu




Fig. 1 The cytotoxic effect of A30P-aSyn-O to primary dopaminergic neurons in culture is mediated by calcineurin. Mouse mesencephalic neurons were treated with 5 μ M of different A30P-aSyn species (monomer, oligomer of fiber) in the absence or in the presence of 2 μ M of CsA. After 24 h of treatment, cell viability was evaluated by LDH release (**A**). The number of neurons per field was quantified (**B**) in the cultures treated with A30P-aSyn-O in the presence or absence of CsA, and immuno-stained with anti-MAP2 antibody (**C**). All experiments were performed at least three times and graphs are represented as mean and SD where * $p > 0.05$, ** $p > 0.01$ and *** $p > 0.001$, Scale bar = 50 μ m

et al. 1998). The levels of tyrosine hydroxylase (TH) and MAP2 were evaluated as indicators of differentiation efficacy as described and demonstrated by our group in Latge et al. (2015) and as shown for TH in Additional file 1: Fig. S3.

Next, we evaluated the cytotoxicity of different concentrations of A30P-aSyn monomers, oligomers, and fibrils, as previously done with primary neurons. As expected, monomers and fibrils were not significantly toxic to differentiated N2a, not even at the concentration of 10 μ M, while 5 and 10 μ M of oligomers were able to kill, respectively, 20% and 42% of the cells (Fig. 3A and Additional file 1: Fig. S2A). Interestingly, non-differentiated N2a were insensitive to oligomers




Fig. 2 A30P-aSyn-O-induced synaptic loss in primary dopaminergic neurons is mediated by calcineurin. Primary mouse midbrain dopaminergic neurons were treated with 5 μ M of aSyn monomers or oligomers in the absence or in the presence of 2 μ M of CsA for 24 h. Cells were immuno-stained with anti-MAP2 and anti-synapsin 1 antibodies (**A**). The number of synapses in each condition was evaluated by counting synaptic puncta (**B**). All experiments were performed at least three times and graphs are represented as mean and SD. Scale bar = 50 μ m

treatment at any concentration (Additional file 1: Fig. S2B) confirming the high sensitivity of dopaminergic neurons to oligomer of aSyn. Again, the pre-treatment of the culture with 2 μ M of CsA significantly protected the cells from oligomer-induced toxicity (Fig. 3A).

To evaluate a direct implication of NFAT in aSyn toxicity, we used VIVIT, a selective peptide inhibitor of NFAT




Fig. 3 A30P-aSyn-O-induced toxicity in differentiated N2a dopaminergic cells is dependent on NFAT activation. Differentiated N2a were treated with different concentrations of A30P-aSyn monomers (M), oligomers (O), and fibrils (F) in the absence or in the presence of 2 μ M of CsA and cellular damage was evaluated by LDH release (A). The specific NFAT inhibitor VIVIT was able to prevent the cellular damage caused by A30P-aSyn-O evaluated by LDH (B), crystal violet (C) or propidium iodide staining (D). All experiments were performed at least three times and graphs are represented as mean and SD where * $p > 0.05$, ** $p > 0.01$ and *** $p > 0.001$

activation. VIVIT blocks only the interaction of CnA with NFAT, making it a very specific inhibitor of NFAT pathway, as it does not interfere with CnA phosphatase activity, as CsA (Noguchi et al. 2004; Aramburu 1999). The cells were pre-treated with 1, 5 or 10 μ M of VIVIT followed by the addition of 10 μ M A30P-aSyn-O, and cell death was evaluated as described (Fig. 3B). We observed a dose dependent inhibition of oligomer-induced cytotoxicity by the analysis of cell membrane integrity loss by propidium iodide (PI) (Fig. 3C) and by crystal violet staining (Fig. 3D). Around 60% of the cells treated with oligomers were positive for PI, while pre-treatment with VIVIT lowered PI signal to around 30%. As expected,

2 μ M of CsA prevented oligomer-induced cytotoxicity. Together these data strongly support the hypothesis that the NFAT pathway is involved in neuronal cell death induced by aSyn oligomers.

To determine whether the NFAT transcription factor is activated by A30P-aSyn-O, we assessed the subcellular localization of NFAT upon treatment of the cells with oligomers. As expected, in untreated, control cells, NFAT was found mainly in the cytosol, and in almost all cells the nuclei were not stained. When cells were treated with A30P-aSyn-O, NFAT could be detected in the nucleus 3 h after treatment (Fig. 4A). Importantly, NFAT-nuclear localization was completely abolished by treatment with CsA or VIVIT (Fig. 4A). The extent of NFAT translocation into the nucleus was quantified by measuring the ratio between the intensities of the signal in the nucleus and in the cytosol, and we found a 3.5-fold increase upon treatment with A30P-aSyn-O (Fig. 4B).

To further confirm that A30P-aSyn-O could activate the NFAT pathway, translocating the TF to the nucleus and activating target genes, we used a plasmid encoding for the firefly luciferase reporter under the control of the NFAT promoter (3 \times NFAT). After transfection with this plasmid, cells were differentiated into DA neurons as described above. As a control, we used that the calcium ionophore ionomycin, a well-known NFAT activator, which caused 2.5-fold increase in the expression of firefly luciferase, confirming that NFAT was activated, migrating to the nucleus, and activating the expression of the reporter gene (Fig. 4C). As expected, CsA and VIVIT abolished the effect induced by ionomycin, by blocking the NFAT pathway (Fig. 4C). Importantly, we found that A30P-aSyn-O activated the transcription of the luciferase reporter gene by 1.3-fold, and again, CsA and VIVIT abolished this effect (Fig. 4D). Taken together, these data show that A30P-aSyn-O induce nuclear translocation and functional activation NFAT, likely mediating cytotoxicity and neuronal death.

To test if NFAT activation was sufficient to induce death of differentiated N2a, cells were transduced with retroviruses encoding CA-NFATc2-ER to stably express a constitutively active NFAT (CA-NFATc2) protein that is activated by tamoxifen (OHT), by fusing the previously characterized CA-NFATc2 to the N-terminally truncated G525R estrogen receptor (ERTM), which is only responsive to OHT (Robbs et al. 2013). The use of a conditioned NFATc2 protein enables temporal control and synchronization of NFAT activation and, therefore, a more detailed analysis of the gene expression profile mediated by this factor and cell death kinetics. Furthermore, this construct bypasses the need for a Ca²⁺ influx to activate NFATc2 protein, reducing the background generated by the induction of other Ca²⁺-responsive transcription factors, such as CREB and




Fig. 4 A30P-aSyn-O induce NFAT translocation into the nucleus and cell death in differentiated N2a dopaminergic cells. Differentiated N2a cells were treated with 10 μ M A30P-aSyn-O for 3 h. **A** Cells were immunostained with anti-NFATc3 and DAPI and imaged on a confocal microscope. The extent of NFAT translocation into nucleus was calculated by measuring the ratio of the red fluorescence intensity in the nucleus by the red fluorescence intensity in the cytosol. Scale bar = 50 μ m. **B** Differentiated N2a cells were co-transfected with pGL4.30 plasmids containing firefly (reporter gene) and renilla luciferase (control gene). The firefly luciferase gene is under the regulation of 3 \times NFAT promoter, while renilla luciferase is under the regulation of a constitutive promoter, serving as a normalizing control. N2a cells were treated with ionomycin 3 μ M (**C**) or A30P-aSyn-O 10 μ M (**D**). After 18 h, a dual-luciferase assay was performed to evaluate NFAT activation measured by firefly luciferase luminescence. Cells were treated with 50–500 nM of OHT (Tamoxifen) as indicated in the X axis and after 48 h cytotoxicity was measured by LDH release (**E**). All experiments were performed at least three times and graphs are represented as mean and SD where * $p > 0.05$, ** $p > 0.01$ and *** $p > 0.001$

MEF2, or of other aSyn-O-induced pathways. As expected, OHT did not induce cell death in differentiated wildtype control N2a cells (data not shown). Interestingly, in differentiated CA-NFATc2-ER N2a expressing cells, OHT induced a marked and concentration dependent cell death (Fig. 4E [OHT]). Altogether, these data indicate that NFAT transcription factor is activated by A30P-aSyn-O and is sufficient to induce cell death in differentiated N2a neurons, suggesting a main role for this transcription factor in PD pathology.

Expression of NFAT-regulated genes changes upon treatment with aSyn oligomers

Since NFAT is a transcription factor, and given its involvement in the aSyn-O-induced cytotoxicity and

synapse loss in both primary mesencephalic cultures and in differentiated N2a cells, we performed real-time qPCR assays to assess the involvement of the NFAT pathway in regulating gene expression in response to aSyn-O. We assembled a real-time qPCR panel of 91 genes related to various cellular processes involved in PD/synucleinopathies, including inflammation, apoptosis, synaptic modulation, and neural development genes (Additional file 1: Table S1), and assessed gene expression alterations in differentiated N2a treated with A30P-aSyn-O, in the absence or in the presence of VIVIT. Genes with at least twofolds up- or down-regulation, and that had their expression normalized by VIVIT (Additional file 1: Table S1), were further validated by real-time qPCR in primary neurons and

in CA-NFATc2-ER N2a cells (Fig. 5). Of the 91 genes tested, we identified 5 that were aSyn-O responsive (twofold up or down-regulated) and modulated by the NFAT pathway, as analyzed by VIVIT inhibition: *Syn1*, *Tubb4*, *Kalrn*, *Bcl-2A1A* and *Bim* (in bold the genes downregulated). We identified 8 genes that were aSyn-O responsive, but not responsive to NFAT inhibition: *Bbc3*, *Mcl1*, *Xiap*, *Pmaip1*, *Bmp4*, *Map2K4*, *Ngf* and *Nos2* (Additional file 1: Table S1). Interestingly the

genes *Syn1*, *Tubb4*, *Kalrn* are known to be involved in formation and maintenance of synapses, and the other two, *Bcl-2A1A* and *Bim* are known to be involved in apoptosis. Furthermore, we found that the levels of synapsin 1 (Syn1) protein are drastically reduced in primary neurons treated with A30P-aSyn-O, supporting that this gene is regulated by the NFAT transcription factor (Fig. 2). Furthermore, the genes that were regulated only by oligomers but did not respond to VIVIT




Fig. 5 Synapsin 1 levels are decreased in the presence of A30P-aSyn oligomers in an NFAT-dependent pathway. Mouse primary hippocampal neurons (A) or differentiated N2a cells (C) were treated with A30P-aSyn-O (10 μ M) in the absence or in the presence of VIVIT (10 μ M) for 18 h. Genes responsive to NFAT pathway modulation found in the panel (*Syn1*, *Tubb4*, *Kalrn*, *Bcl-2A1A* and *Bim*) were validated by real time PCR. CA-NFAT-ER N2a cells were treated with 150 of OHT (Tamoxifen) and were analyzed after 24 h by real-time-PCR for the same genes (E). Western blot analyses were made for the same cells and treatments to assess expression level of Syn1 protein (B, D, F; left). β -Actin was used as loading control. Graphical representation of band intensities of Syn1 normalized to β -actin (B, D, F; right). Mouse primary hippocampal neurons were treated with 10 μ M of A30P-aSyn-O in the absence or presence of 2 μ M of CsA or 10 μ M of VIVIT for 24 h. Cells were immunostained with anti-MAP2 and anti-synapsin-1 antibodies (G). All experiments were performed at least three times and graphs are represented as mean and SD where * $p > 0.05$, ** $p > 0.01$ and *** $p > 0.001$. Scale bar = 10 μ m

NFAT-pathway inhibition, suggest that these genes are likely enrolled in other cellular pathways.

To validate the aSyn-O NFAT regulated genes (*Syn1*, *Tubb4*, *Kalrn*, *Bcl-2A1A* and *Bim*), we first repeated the real-time qPCR in primary neurons and in differentiated N2a (Fig. 5A, C). Of the five tested only *Syn1* gene showed the same pattern of expression in both models. Surprisingly, NFAT pathway inhibition by VIVIT completely reversed the suppression of this gene induced by aSyn-O. While *Tubb4* had the same pattern of regulation as *Syn1*, the changes were below the threshold we considered significant in real-time PCR (Ct+ twofold).

Furthermore, to explore a possible regulation of these gene exclusively and directly by NFAT activation, CA-NFATc2-ER N2a cells were treated with OHT. In this model, only *Syn1* and *Tubb4* were at least twofold down regulated after OHT treatment, indicating that the NFAT transcription factor pathway can directly and sufficiently modulate these genes expression at mRNA level (Fig. 5E). It is important to emphasize that mRNA and protein levels were assessed at a time point before massive cell death could be observed (18 h for primary neurons and differentiated N2a cells and 24 h for CA-NFAT-ER-expressing cells), greatly reducing a cell-death bias in these quantifications. To our knowledge, this is the first demonstration of a possible direct regulation of the *Syn1* gene by NFAT transcription factor. Consistently, we identified two well conserved putative NFAT-binding sites in the *Syn1* promoter region between five different animal species (Additional file 1: Table S2), whereas no putative NFAT-binding site was found in genes responsive to aSyn-O but irresponsive to VIVIT (genes not regulated by NFAT pathway).

Since the levels of *Syn1* mRNA were the most responsive to A30P-aSyn-O treatment and to NFAT pathway inhibition, we further analyzed *Syn1* protein levels in primary neurons and in differentiated N2a cells. Consistent with the reduction in mRNA levels, A30P-aSyn-O significantly reduced *Syn1* protein levels (approximately twofold) (Fig. 5B, D). This effect was completely abolished by CsA or VIVIT treatment, strongly suggesting a role of the NFAT pathway in this regulation. Finally, the sole activation of NFAT (in CA-NFATc2-ER N2a by OHT treatment) induced a similar reduction of *Syn1* levels, demonstrating that NFAT can regulate (direct or indirectly) the *Syn1* gene (Fig. 5F). To further illustrate this regulation, VIVIT treatment also completely reversed the effects of A30P-aSyn-O on presynaptic vesicles, as seen by *Syn1* staining in neurons, and restored neuronal morphology to levels comparable to control and CsA treatment (Fig. 5G). Together, these data demonstrate that A30P-aSyn-O can disrupt neuronal synapses by the activation of NFAT signaling pathway and subsequent

downregulation of *Syn1* expression suggesting NFAT pathway inhibition might be a target for pharmacological modulation in synucleinopathies.

Discussion

In this study, we took advantage of the increased oligomerization propensity of a mutant variant of aSyn associated with familial forms of PD (A30P-aSyn) to ascertain the signaling cascades triggered by oligomer-enriched aSyn preparations. We investigated the role of calcineurin-NFAT signaling pathway in the neurotoxicity induced by aSyn oligomeric and fibrillar species. Importantly, we show, for the first time, the direct implication of the NFAT family of transcription factors pathway in the cytotoxicity and synaptic regulation induced by a particular type of extracellular aSyn oligomers. We show that extracellular aSyn oligomers, but not fibrillar species, strongly induce cell death and loss of the pre-synaptic protein synapsin 1, and that these effects are completely reverted by calcineurin (CnA) inhibition with cyclosporin A (CsA) and, surprisingly, also with VIVIT, a specific peptide inhibitor of the CnA-NFAT pathway. This suggests NFAT might be an important transcription factor in PD. Furthermore, NFAT pathway regulation is sufficient, as shown by exclusive NFAT activation (CA-NFATc2-ER N2a), and necessary to induce PD-related cellular phenotypes, including neural cell death, possibly by regulating important genes involved in apoptosis and synapsin 1 expression.

aSyn overexpression, extracellular accumulation, or administration, have been used to generate numerous cell and animal models of PD, as this protein is considered a major culprit in PD (Domingues et al. 2022). As previously shown, oligomeric WT or mutant aSyn induce cell death in dopaminergic cell lines and in primary neuronal cultures, alter functional neuronal markers, decrease synaptic plasticity, and induce memory deficits (Martin et al. 2012; Domingues et al. 2022; Caraveo et al. 2014b). Cells must tightly regulate Ca^{2+} homeostasis to prevent pathological disorders and cell death due to excitotoxicity (Wojda et al. 2008). Extracellular oligomeric forms of aSyn induce Ca^{2+} overload into neurons, and the consequent activation of downstream pathways leads to pathological alterations and, ultimately, to cell death and several other PD-related alterations (Martin et al. 2012; Ferreira et al. 2017; Chan et al. 2007; Hurley et al. 2013; Adamczyk and Strosznajder 2006; Danzer et al. 2007). One hypothesis is that aSyn certain oligomers may induce the formation of Ca^{2+} -permeable pores at the plasma membrane, in accord to what has been postulated for other aggregating proteins, such as amyloid- β peptides and prion proteins (Domingues et al. 2022; Hetiarachchi et al. 2009).

One of the best-characterized pathways activated by Ca^{2+} influx is the Ca^{2+} -CaM-dependent serine/threonine phosphatase calcineurin, an essential enzyme that plays a key role in neurite extension, synaptic plasticity, memory, and learning (Zeng et al. 2001), and is implicated as a key mediator of aSyn toxicity. Pharmacological inhibition of the catalytic subunit of calcineurin, calcineurin A (CnA), with clinically used inhibitors, such as FK506 and CsA, can reduce aSyn toxicity in different models (Martin et al. 2012; Caraveo et al. 2014; Kitamura et al. 1994; Guo et al. 2001; Yuan et al. 2010). Although the role of Ca^{2+} -CaM-CnA pathway in aSyn induced phenotypes has been documented, the downstream signaling pathways are still obscure. One of the main transcription factors targeted by CnA dephosphorylation is the NFAT-family (Loh et al. 1996). Here, we showed that A30P-aSyn-O can activate the NFAT transcription factor leading to its translocation into the nucleus and activation of reporter gene (Fig. 4). Moreover, we showed that inhibition of CnA with CsA and with VIVIT, a specific inhibitor of the CnA-NFAT pathway, can revert this transcription factor activation and block aSyn-O neurotoxicity, as characterized by the almost complete inhibition of cell death, reversal of neural ramification deterioration, and loss of pre-synaptic synapsin 1 positive puncta formation (Figs. 1, 2 and 3). Consistently, the NFAT transcription factor has already been demonstrated to be important in neural and axonal growth and development (Graef et al. 2003, 2001; Nguyen and Giovanni 2008), survival (Ulrich et al. 2012), and death (Luoma and Zirpel 2008; Jayanthi et al. 2005; Liu et al. 1991), being localized in the nucleus of neurons in aSyn transgenic mice in postmortem brain tissue from PD patients (Caraveo et al. 2014), it can be activated by aSyn in mice neurons and its modulation by the non-NFAT-specific inhibitor (CsA) can ameliorated the aSyn-induced loss of mDA neurons (Luo et al. 2014). Further, Ca^{+} /CnA/NFAT signaling pathway is linked to several nervous system diseases as Down Syndrome, Alzheimer's, Huntington's, traumatic brain injuries, amyotrophic lateral sclerosis, and others (Kipanyula et al. 2016; Park et al. 2009; Minami 2014; Sompol and Norris 2018) suggesting a relevant role for this transcription factor pathway in nervous system physiological maintenance and development, including Parkinson's disease.

However, the direct role of this transcription factor in neuronal degeneration and the regulation of the expression of relevant PD-related genes has not been determined. After the analysis of a panel of 91 genes related to various cellular processes involved in PD/synucleinopathies (including inflammation, apoptosis, synaptic modulation, and neural development) by real-time qPCR, we found several putative genes regulated by NFAT induced

by A30P-aSyn-O. In differentiated N2a cells, *Bcl2a* and *Bim*, two apoptotic related proteins, seemed to be regulated by NFAT. However, after validation in primary neurons and in N2a cells with only the NFAT pathway specifically activated (NFAT-ER), we found their expression was close to the detection limit of the technique, and that their pattern varied between different cell types. NFAT directly regulates the expression of several apoptosis-related genes such as *Fas-L*, *Nur77*, *c-Flip* and *TNF- α* , *A1* and *Bcl2* in several other cell types (Mognol et al. 2016; Lucena et al. 2016; Teixeira et al. 2016). In the future, further analysis will be needed to unveil how NFAT pathway regulates neuron cell death induced by aSyn-O, since both its inhibition and exclusive activation is sufficient to modulate this process.

Interestingly, one gene that might be directly regulated by NFAT at the transcriptional and translational level is *Syn1*, that encodes synapsin 1, as this was validated in our three different cells models (Fig. 5). Several recent studies have suggested that intra- or extracellular aSyn overexpression or accumulation can induce presynaptic dysfunction by disturbing vesicular trafficking, leading to defects in neurotransmitter release (Nemani et al. 2010; Gitler et al. 2008; Soper et al. 2008; Diao et al. 2013; Choi et al. 2013) and to the loss of several presynaptic proteins important for neurotransmitter release and synapse formation (Larson et al. 2017; Nemani et al. 2010; Scott et al. 2010). Synapsin 1 is of major importance because of its role in vesicle trafficking. In resting conditions, synapsin 1 attaches the vesicle to the actin-based cytoskeleton. During excitation, and upon phosphorylated by different kinases, it detaches from the vesicles facilitating neurotransmitter release and mediates the binding of recycling vesicles to the actin cytoskeleton (Paonessa et al. 2013; Roy et al. 2007; Hosaka et al. 1999). Interestingly, aSyn aggregation has been suggested to down-regulate the expression of synapsin 1, correlating with PD phenotypes such as locomotion and memory impairment (Larson et al. 2017; Nemani et al. 2010; Scott et al. 2010; Spinelli et al. 2014). A recent study also suggested that synapsins are implicated in the inhibition of synaptic vesicle exocytosis by aSyn (Atias et al. 2019). Finally, at a molecular level, the transcriptional expression of synapsin genes (*Syn1*) is down-regulated in vivo and in vitro by aSyn oligomers (Larson et al. 2017). However, although synapsin 1 was already described as an important target for oligomeric aSyn, the molecular mechanisms involved in the transcriptional regulation of synapsin 1 by aSyn were unknown. CnA inhibition has been shown to reverse neuritic beading and rescue structural disruption of neuronal network in the presence of A β (Kuchibhotla et al. 2008), and to regulate different




Fig. 6 Schematic representation of the participation of NFAT on synapse degeneration in synucleinopathies. A specific population of aSyn-O present in the extracellular milieu could be inserted in the plasma membrane leading to leakage of calcium to the interior of the neurons. Upon calcium binding, activation of calcineurin takes place. This phosphatase dephosphorylates the hyperphosphorylated, inactive NFAT leading to its activation and translocation to the nucleus. There, NFAT binds to its cognate promoter sequences including the one that regulates the expression of the gene of synapsin 1 (*Syn1*). NFAT downregulates the expression of this gene decreasing the amount synapsin 1, a protein that is involved in vesicle trafficking facilitating neurotransmitter release. This cascade of events leads to synapse degeneration one of the events observed in PD and other synucleinopathies

proteins involved in neurotransmitter release, including synapsins, synaptotagmin, rabphilin2A, synaptobrevin, and dephosphins (Greengard et al. 1993). However, we show here for the first time, that NFAT transcription factor has two possible highly conserved putative binding sites in the *Syn1* promoter, and is necessary and sufficient for regulating *Syn1*, leading to its downregulation at the transcriptional (mRNA) and translational level (protein). NFAT inhibition leads to synapsin 1 expression and accumulation at presynaptic puncta in neurons, where it performs its normal function. NFAT can bind to specific DNA-responsive elements defined as (A/T)GGAAA(A/N) (A/T/C) to activate or deactivate gene transcription, either alone or in synergy with several other transcriptional regulators (Mognol et al. 2012, 2016). Interestingly, we identified two well-conserved (at least in five different animal species) putative NFAT-responsive elements in the *Syn1* promoter region, adding more evidence supporting NFAT regulation of synapsin 1 gene translation. In the future, it will be important to investigate the involvement of NFAT in the regulation of *Syn1* through techniques such as Chip-qPCR, CRISPR-dCas9 mutation targeting the potential binding sites, and other methods to

provide evidence for or against NFAT binding to *Syn1* promoter.

Therefore, our current results reveal a previously undocumented mechanism whereby small oligomeric aSyn species may disturb synapses in PD, possibly affecting memory function and cognitive ability (Fig. 6). Our results further suggest that such pathological mechanisms may be effectively targeted by pharmacological inhibition of NFAT by selective small-molecule inhibitors of calcineurin-NFAT signaling that mimic VIVIT, or by already-approved drugs as CsA and FK506.

Conclusions

In summary, our data shows that aSyn-O exogenously given to neurons leads to the activation of CaN/NFAT pathway that is sufficient and necessary to induce a neurodegeneration phenotype like PD, as neuron cells death and loss of functional synapses as shown by the loss of neuron ramification and synapsin-1 punctas. CnA inhibitor, cyclosporin A, or the specific NFAT inhibitor, VIVIT, were able to completely revert aSyn-O induced phenotype where exclusive NFAT activation led to neurodegeneration. Furthermore, we determined for the first time that aSyn-O through activation of CnA/NFAT pathway regulates synapsin-1 mRNA and protein expression

possibly through binding to two putative NFAT DNA binding site present on *SYN1* promoter region. This is the first time that a direct role for CnA/NFAT pathway is implicated in aSyn-O induced neuron cell death and loss of synapsin-1 *punctas* and of a possible direct regulation of Syn-1 expression by NFAT proteins.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s10020-023-00704-8>.

Additional file 1. Supplementary Figures and Tables.

Acknowledgements

We thank the technical support and assistance of Santiago Francisco da Silva Alonso and Christiane Fahlbusch.

Author contributions

BR and DF conceptualization conceived the idea; RS, BR, JF, PS and AK methodology and experimental performance; RS, BR, DF and TO conducting research; RS, BR, DF and TO writing original draft preparation.

Funding

TFO is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—EXC 2067/1-390729940, and by SFB1286 (B8). DF is supported by the Federal Brazilian Funding Agencies, CNPq and Capes, and by the State of Rio de Janeiro Funding Agency, Faperj. RS is supported by the Federal Brazilian Funding Agencies, CNPq and Capes, and by the State of Rio de Janeiro Funding Agency, Faperj.

Availability of data and materials

The main data generated or analyzed during this study are included in this published article (and its Additional files). Any that is not present on the manuscript will be readily available under request.

Declarations

Ethics approval and consent to participate

No human samples or analysis were made. For primary neuron culture, mice were bred and maintained under specific pathogen free conditions in the animal facility of the University Medical Center Göttingen (Göttingen, Germany). Animal procedures were performed in accordance with the European Community (Directive 2010/63/EU), institutional and national guidelines (license number 19.3213).

Consent for publication

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. I further confirm that the order of authors listed in the manuscript has been approved by all of us.

Competing interests

The authors declare that they have no competing interests.

Received: 31 March 2023 Accepted: 18 July 2023
Published online: 18 August 2023

References

- Adamczyk A, Strosznajder JB. Alpha-synuclein potentiates Ca²⁺ influx through voltage-dependent Ca²⁺ channels. *NeuroReport*. 2006;17(18):1883–6.
- Aramburu J. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. *Science* (80-). 1999;285(5436):2129–33. <https://doi.org/10.1126/science.285.5436.2129>.
- Aramburu J, Yaffe MB, López-Rodríguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. *Science* (80-). 1999;285(5436):2129–33.
- Atias M, Tevet Y, Sun J, Stavsky A, Tal S, Kahn J, et al. Synapsins regulate α-synuclein functions. *Proc Natl Acad Sci USA*. 2019;166(23):11116–8.
- Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VMY, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. *Am J Pathol*. 1998;152(4):879.
- Braak H, Sandmann-Keil D, Gai W, Braak E. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry. *Neurosci Lett*. 1999;265(1):67–9.
- Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*. 2003;24(2):197–211.
- Braak H, Rüb U, Jansen Steur ENH, Del Tredici K, De Vos RAI. Cognitive status correlates with neuropathologic stage in Parkinson disease. *Neurology*. 2005;64(8):1404–10.
- Braga CA, Follmer C, Palhano FL, Khattar E, Freitas MS, Romão L, et al. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. *J Mol Biol*. 2011;405(1):254–73.
- Brown DR. Oligomeric alpha-synuclein and its role in neuronal death. *IUBMB Life*. 2010;62(5):334–9.
- Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. *Nat Rev Neurosci*. 2008;9(10):741–5.
- Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, et al. Calcineurin determines toxic versus beneficial responses to α-synuclein. *Proc Natl Acad Sci USA*. 2014;111(34):E3544–52.
- Caviness JN, Lue LF, Adler CH, Walker DG. Parkinson's disease dementia and potential therapeutic strategies. *CNS Neurosci Ther*. 2011;17(1):32–44.
- Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. *Nature*. 2007;447(7148):1081–6.
- Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. α-Synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet*. 2004;364(9440):1167–9.
- Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. *Proc Natl Acad Sci USA*. 2013;110(10):4087–92.
- Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. *Nat Med*. 1998;4(11):1318–20.
- Crabtree GR. Generic signals and specific outcomes: signaling through Ca²⁺, calcineurin, and NF-AT. *Cell*. 1999;96(5):611–4.
- Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of α-synuclein oligomers induce calcium influx and seeding. *J Neurosci*. 2007;27(34):9220–32.
- Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, et al. Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. *FASEB J*. 2011;25(1):326.
- Diao J, Burré J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, et al. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. *Elife*. 2013;2: e00592.
- Diógenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, Guerreiro P, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. *J Neurosci*. 2012;32(34):11750–62.
- Domingues R, Sant'Anna R, da Fonseca ACC, Robbs BK, Foguel D, Outeiro TF. Extracellular alpha-synuclein: sensors, receptors, and responses. *Neurobiol Dis*. 2022;168: 105696.
- El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. *FASEB J*. 2006;20(3):419–25.
- Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. *J Neurosci*. 2010;30(20):6838–51.
- Ferreira DG, Temido-Ferreira M, Miranda HV, Batalha VL, Coelho JE, Szegő ÉM, et al. α-Synuclein interacts with PrP C to induce cognitive impairment through mGluR5 and NMDAR2B. *Nat Neurosci*. 2017;20(11):1569–79.

- Follmer C, Romão L, Einsiedler CM, Porto TCR, Lara FA, Moncores M, et al. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of α -synuclein. *Biochemistry*. 2007;46(2):472–82.
- Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, et al. Phosphorylated α -synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. *FASEB J*. 2011;25(12):4127–37.
- Fujioka S, Ogaki K, Tacik PM, Utti RJ, Ross OA, Wszolek ZK. Update on novel familial forms of Parkinson's disease and multiple system atrophy. *Park Relat Disord*. 2014;20:529–34.
- Gertz HJ, Siegers A, Kuchinke J. Stability of cell size and nucleolar size in Lewy body containing neurons of substantia nigra in Parkinson's disease. *Brain Res*. 1994;637(1–2):339–41.
- Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, et al. The Parkinson's disease protein α -synuclein disrupts cellular Rab homeostasis. *Proc Natl Acad Sci USA*. 2008;105(1):145–50.
- Graef IA, Chen F, Crabtree GR. NFAT signaling in vertebrate development. *Curr Opin Genet Dev*. 2001;11:505–12.
- Graef IA, Wang F, Charron F, Chen L, Neilson J, Tessier-Lavigne M, et al. Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. *Cell*. 2003;113(5):657–70.
- Greengard P, Valtorta F, Czernik AJ, Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. *Science* (80-). 1993;259(5096):780–5.
- Guo X, Dillman JF, Dawson VL, Dawson TM. Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. *Ann Neurol*. 2001;50(1):6–16.
- Hettiarachchi NT, Parker A, Dallas ML, Pennington K, Hung CC, Pearson HA, et al. α -Synuclein modulation of Ca^{2+} signaling in human neuroblastoma (SH-SY5Y) cells. *J Neurochem*. 2009;111(5):1192–201.
- Hosaka M, Hammer RE, Südhof TC. A phospho-switch controls the dynamic association of synapsins with synaptic vesicles. *Neuron*. 1999;24(2):377–87.
- Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson's disease is associated with altered expression of Ca V1 channels and calcium-binding proteins. *Brain*. 2013;136(7):2077–97.
- Hurtley SM. α -Synuclein and aging. *Sci Signal*. 2010;3(141):ec303.
- Jayanthi S, Deng X, Ladenheim B, McCoy MT, Cluster A, Cai NS, et al. Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. *Proc Natl Acad Sci USA*. 2005;102(3):868–73.
- Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science*. 2003;300(5618):486–9.
- Kipanyula MJ, Kimaro WH, Etet PFS. The emerging roles of the calcineurin-nuclear factor of activated T-lymphocytes pathway in nervous system functions and diseases. *J Aging Res*. 2016. <https://doi.org/10.1155/2016/5081021>.
- Kitamura Y, Itano Y, Kubo T, Nomura Y. Suppressant effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. *J Neuroimmunol*. 1994;50(2):221–4.
- Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. *Nat Med*. 2008;14(5):504–6.
- Koss DJ, Erskine D, Porter A, Palmoski P, Menon H, Todd OGJ, et al. Nuclear α -synuclein is present in the human brain and is modified in dementia with Lewy bodies. *Acta Neuropathol Commun*. 2022;10(1):1–18.
- Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding α -synuclein in Parkinson's disease. *Nat Genet*. 1998;18(2):106–8.
- Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. A β plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. *Neuron*. 2008;59(2):214–25.
- Larson ME, Greimel SJ, Amar F, LaCroix M, Boyle G, Sherman MA, et al. Selective lowering of synapsins induced by oligomeric α -synuclein exacerbates memory deficits. *Proc Natl Acad Sci USA*. 2017;114(23):E4648–57.
- Latge C, Cabral KMS, De Oliveira GAP, Raymundo DP, Freitas JA, Johanson L, et al. The solution structure and dynamics of full-length human cerebral dopamine neurotrophic factor and its neuroprotective role against α -synuclein oligomers. *J Biol Chem*. 2015;290(33):20527–40.
- Lázaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic comparison of the effects of α -synuclein mutations on its oligomerization and aggregation. *PLoS Genet*. 2014;10(11):e1004741.
- Lee SJ. Origins and effects of extracellular α -synuclein: implications in Parkinson's disease. *J Mol Neurosci*. 2008;34:17–22.
- Lee JC, Langen R, Hummel PA, Gray HB, Winkler JR. α -Synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease. *Proc Natl Acad Sci USA*. 2004;101(47):16466–71.
- Li H, Rao A, Hogan PG. Interaction of calcineurin with substrates and targeting proteins. *Trends Cell Biol*. 2011;21(2):91–103.
- Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell*. 1991;66(4):807–15.
- Loh C, Shaw KTY, Carew J, Viola JPB, Luo C, Perrino BA, et al. Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. *J Biol Chem*. 1996;270(35):20653–9.
- Lucena PI, Faget DV, Pachulec E, Robaina MC, Klumb CE, Robbs BK, et al. NFAT2 isoforms differentially regulate gene expression, cell death, and transformation through alternative N-terminal domains. *Mol Cell Biol*. 2016;36(1):119–31.
- Luo J, Sun L, Lin X, Liu G, Yu J, Parisiadou L, et al. A calcineurin- and NFAT-dependent pathway is involved in α -synuclein-induced degeneration of midbrain dopaminergic neurons. *Hum Mol Genet*. 2014;23(24):6567–74.
- Luoma JI, Zirpel L. Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. *J Neurosci*. 2008;28(12):3159–69.
- Martin ZS, Neugebauer V, Dineley KT, Kaye R, Zhang W, Reese LC, et al. α -Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleinopathies. *J Neurochem*. 2012;120(3):440–52.
- Minami T. Calcineurin-NFAT activation and DSCR-1 auto-inhibitory loop: how is homeostasis regulated? *J Biochem*. 2014;155(4):217–26. <https://doi.org/10.1093/jb/mvu006>.
- Mognol GP, De Araujo-Souza PS, Robbs BK, Teixeira LK, Viola JPB. Transcriptional regulation of the c-Myc promoter by NFAT1 involves negative and positive NFAT-responsive elements. *Cell Cycle*. 2012;11(5):1014–28.
- Mognol GP, Carneiro FRG, Robbs BK, Faget DV, Viola JPB. Cell cycle and apoptosis regulation by NFAT transcription factors: new roles for an old player. *Cell Death Dis*. 2016;7(4):e2199.
- Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of α -synuclein reduces neurotransmitter release by inhibiting synaptic vesicle re-clustering after endocytosis. *Neuron*. 2010;65(1):66–79.
- Nguyen T, Di Giovanni S. NFAT signaling in neural development and axon growth. *Int J Dev Neurosci*. 2008;26:141–5.
- Noguchi H, Matsushita M, Okitsu T, Moriwaki A, Tomizawa K, Kang S, et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. *Nat Med*. 2004;10(3):305–9.
- Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-related process: a hypothesis. *Lancet Neurol*. 2004;3(8):496–503.
- Osterberg VR, Spinelli KJ, Weston LJ, Luk KC, Woltjer RL, Unni VK. Progressive aggregation of α -synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of Parkinsonism. *Cell Rep*. 2015;10(8):1252–60.
- Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, et al. Formation of toxic oligomeric α -synuclein species in living cells. *PLoS ONE*. 2008;3(4):e1867.
- Paleologou KE, Kragh CL, Mann DMA, Salem SA, Al-Shami R, Allsop D, et al. Detection of elevated levels of soluble α -synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. *Brain*. 2009;132(4):1093–101.
- Paonessa F, Latifi S, Scarongella H, Cesca F, Benfenati F. Specificity protein 1 (Sp1)-dependent activation of the synapsin I gene (SYN1) is modulated by RE1-silencing transcription factor (REST) and 5'-cytosine-phosphoguanine (CPG) methylation. *J Biol Chem*. 2013;288(5):3227–39.
- Park J, Yaseen NR, Hogan PG, Rao A, Sharma S. Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells. *J Biol Chem*. 1995;270(35):20653–9.

- Park J, Oh Y, Chung KC. Two key genes closely implicated with the neuro-pathological characteristics in Down syndrome: DYRK1A and RCAN1. *BMB Rep*. 2009;42(1):6–15.
- Pinho R, Paiva I, Jerčić KG, Fonseca-Ornelas L, Gerhardt E, Fahlbusch C, et al. Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. *Hum Mol Genet*. 2019;28(1):31–50.
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* (80-). 1997;276(5321):2045–7.
- Robbs BK, Lucena PI, Viola JPB. The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF- α expression. *Biochim Biophys Acta Mol Cell Res*. 2013;1833(8):2016–28.
- Roy S, Winton MJ, Black MM, Trojanowski JQ, Lee VMY. Rapid and intermittent cotransport of slow component-b proteins. *J Neurosci*. 2007;27(12):3131–8.
- Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. *J Neurosci*. 2010;30(24):8083–95.
- Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. *Science* (80-). 2003;302(5646):841.
- Sompol P, Norris CM. Ca²⁺, astrocyte activation and calcineurin/NFAT signaling in age-related neurodegenerative diseases. *Front Aging Neurosci*. 2018;10(JUL):199.
- Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ, et al. alpha-Synuclein-induced aggregation of cytoplasmic vesicles in *Saccharomyces cerevisiae*. *Mol Biol Cell*. 2008;19(3):1093–103.
- Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. alpha-Synuclein in Lewy bodies. *Nature*. 1997;388(6645):839–40.
- Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, et al. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. *J Neurosci*. 2014;34(6):2037–50.
- Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. *Neurology*. 1994;44(3):437.
- Teixeira LK, Carrossini N, Sécca C, Kroll JE, DaCunha DC, Faget DV, et al. NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes. *Cell Cycle*. 2016;15(17):2346–59.
- Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. *Am J Pathol*. 1997;150(1):119.
- Tremblay RG, Sikorska M, Sandhu JK, Lanthier P, Ribocco-Lutkiewicz M, Bani-Yaghoob M. Differentiation of mouse Neuro 2A cells into dopamine neurons. *J Neurosci Methods*. 2010;186(1):60–7.
- Ulrich JD, Kim MS, Houlihan PR, Shutov LP, Mohapatra DP, Strack S, et al. Distinct activation properties of the nuclear factor of activated T-cells (NFAT) isoforms NFATc3 and NFATc4 in neurons. *J Biol Chem*. 2012;287(45):37594–609.
- Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. *Proc Natl Acad Sci USA*. 2011;108(10):4194–9.
- Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. *IUBMB Life*. 2008;60(9):575–90.
- Wu G, Fang Y, Lu ZH, Ledeen RW. Induction of axon-like and dendrite-like processes in neuroblastoma cells. *J Neurocytol*. 1998;27(1):1–14.
- Yuan Y, Sun J, Zhao M, Hu J, Wang X, Du G, et al. Overexpression of alpha-synuclein down-regulates BDNF expression. *Cell Mol Neurobiol*. 2010;30:939–46.
- Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol*. 2004;55(2):164–73.
- Zeng H, Chattarji S, Barbarosie M, Rondi-Reig L, Philpot BD, Miyakawa T, et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. *Cell*. 2001;107(5):617–29.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

